The molecular basis of myocardial hypertrophy and heart failure

Trends in Molecular Medicine

Volumn 9, Issue 7, 2003, Pages 313-321

  Ritter, Oliver ^a   Neyses, Ludwig ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; DISEASE COURSE; ENDOCRINE FUNCTION; HEART DISEASE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; METABOLISM; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SODIUM URINE LEVEL; SYMPTOMATOLOGY; WATER RETENTION;

EID: 0042427643     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(03)00114-X     Document Type: Review

References (94)

1. Frey, N. and Olson, E.N. (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45-79
2. Braunwald, E. and Bristow, M.R. (2000) Congestive heart failure: fifty years of progress. Circulation 102, 14-23
3. Hunter, J.J. and Chien, K.R. (1999) Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341, 1276-1283
4. Lloyd-Jones, D.M. et al. (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106, 3068-3072
5. Schwartz, K. and Mercadier, J.J. (1996) Molecular and cellular biology of heart failure. Curr. Opin. Cardiol. 11, 227-236
6. Pratt, C.M. et al. (1995) Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators. Am. J. Cardiol. 75, 1244-1249
7. Maron, B.J. et al. (2000) Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102, 858-864
8. Roberts, R. and Schwartz, K. (2000) Myocardial diseases. Circulation 102 (Suppl. 4), 34-39
9. Eckardt, L. et al. (2000) Arrhythmias in heart failure: current concepts of mechanisms and therapy. J. Cardiovasc. Electrophysiol. 11, 106-117
10. Nguyen-Tran, V.T. et al. (2000) A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages. Cell 102, 671-682
11. Schnee, J.M. and Hsueh, W.A. (2000) Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc. Res. 46, 264-268
12. Force, T. et al. (2002) Stretch-activated pathways and left ventricular remodeling. J. Card. Fail. 8, 351-358
13. Brancaccio, M. et al. (2003) Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9, 68-75
14. Fatkin, D. and Graham, R.M. (2002) Molecular mechanisms of inherited cardiomyopathies. Physiol. Rev. 82, 945-980
15. Swynghedauw, B. (1999) Molecular mechanisms of myocardial remodeling. Physiol. Rev. 79, 215-262
16. Senbonmatsu, T. et al. (2000) Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J. Clin. Invest. 106, R25-R29
17. Godecke, A. et al. (1998) Coronary hemodynamics in endothelial NO synthase knockout mice. Circ. Res. 82, 186-194
18. Esposito, G. et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85-92
19. Anversa, P. and Nadal-Ginard, B. (2002) Myocyte renewal and ventricular remodelling. Nature 415, 240-243
20. Lompre, A.M. et al. (1979) Myosin isoenzyme redistribution in chronic heart overload. Nature 282, 105-107
21. Siehl, D. et al. (1985) Faster protein and ribosome synthesis in thyroxine-induced hypertrophy of rat heart. Am. J. Physiol. 248, C309-C319
22. Poole-Wilson, P.A. (2002) Treatment of acute heart failure: out with the old, in with the new. J. Am. Med. Assoc. 287, 1578-1580
23. Corti, R. et al. (2001) Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104, 1856-1862
24. Anversa, P. and Kajstura, J. (1998) Myocyte cell death in the diseased heart. Circ. Res. 82, 1231-1233
25. Elsasser, A. et al. (2001) The role of apoptosis in myocardial ischemia: a critical appraisal. Basic Res. Cardiol. 96, 219-226
26. Hannan, R.D. et al. (1996) Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes. J. Biol. Chem. 271, 3213-3220
27. Hannan, R.D. et al. (1995) Regulation of rDNA transcription factors during cardiomyocyte hypertrophy induced by adrenergic agents. J. Biol. Chem. 270, 8290-8297
28. Morgan, H.E. et al. (1987) Biochemical mechanisms of cardiac hypertrophy. Annu. Rev. Physiol. 49, 533-543
29. Hwang, J.J. et al. (2001) Genomics and the pathophysiology of heart failure. Curr. Cardiol Rep. 3, 198-207
30. Schwartz, K. et al. (1993) The molecular biology ofheart failure. J. Am. Coll. Cardiol. 22, 30A-33A
31. Ritter, O. et al. (1999) Expression of atrial myosin light chains but not a-myosin heavy chains is correlated in vivo with increased ventricular function in patients with hypertrophic obstructive cardiomyopathy. J. Mol. Med. 77, 677-685
32. Miyata, S. et al. (2000) Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ. Res. 86, 386-390
33. Morano, I. (1999) Tuning the human heart molecular motors by myosin light chains. J. Mol. Med. 77, 544-555
34. Schaub, M.C. et al. (1998) Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms. Cardiovasc. Res. 37,381-404
35. Thierfelder, L. et al. (1994) Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701-712
36. Gerull, B. et al. (2002) Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30, 201-204
37. Hein, S. et al. (2000) The role of the cytoskeleton in heart failure. Cardiovasc. Res. 45, 273-278
38. Frank, K.F. et al. (2002) Modulation of SERCA: implications for the failing human heart. Basic Res. Cardiol. 97 (Suppl. 1), 172-178
39. 2+ load in human heart failure. Basic Res. Cardiol. 97 (Suppl.), 163-171
40. Eisner, D.A. et al. (2000) Integrative analysis of calcium cycling in cardiac muscle. Circ. Res. 87, 1087-1094
41. Schmitt, J.P. et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413
42. Marx, S.O. et al. (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101, 365-376
43. Marks, A.R. (2001) Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J. Mol. Cell. Cardiol. 33, 615-624
44. Terracciano, C. (2002) Functional consequences of Na/Ca exchanger overexpression in cardiac myocytes. Ann. N. Y Acad. Sci. 976, 520-527
45. Sipido, K.R. et al. (2002) Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy? Cardiovasc. Res. 53, 782-805
46. Conway, S.J. and Koushik, S.V. (2001) Cardiac sodium-calcium exchanger: a double-edged sword. Cardiovasc. Res. 51, 194-197
47. Pogwizd, S.M. et al. (2001) Arrhythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual β-adrenergic responsiveness. Circ. Res. 88, 1159-1167
48. 2+-ATPase in a rat model of heart failure. Circulation 104, 1424-1429
49. Zhao, W. et al. (2003) Combined phospholamban ablation and SERCAla overexpression result in a new hyperdynamic cardiac state. Cardiovasc. Res. 57, 71-81
50. Song, Q. et al. (2003) Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest. 111, 859-867
51. Eisner, D.A. and Trafford, A.W. (2002) Heart failure and the ryanodine receptor: does Occam's razor rule? Circ. Res. 91, 979-981
52. Marks, A.R. (2003) A guide for the perplexed: towards an understanding of the molecular basis of heart failure. Circulation 107, 1456-1459
53. 2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices. Circ. Res. 91, 517-524
54. Gomez, A.M. et al. (1997) Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 276, 800-806
55. Bers, D.M. (2002) Cardiac excitation-contraction coupling. Nature 415, 198-205
56. 2+-ATPase in myogenic cells. J. Biol. Chem. 271, 30816-30822
57. Hammes, A. et al. (1998) Overexpression of the sarcolemmal calcium pump in the myocardium of transgenic rats. Circ. Res. 83, 877-888
58. Schuh, K. et al. (2001) The plasmamembrane calmodulin-dependent calcium pump: a major regulator of nitric oxide synthase I. J. Cell Biol. 155, 201-205
59. Hasenfuss, G. et al. (1997) Calcium handling proteins in the failing human heart. Basic Res. Cardiol. 92 (Suppl. 1), 87-93
60. Lohse, M.J. et al. (1996) Mechanisms of β-adrenergic receptor desensitization: from molecular biology to heart failure. Basic Res. Cardiol. 91 (Suppl. 2), 29-34
61. Molkentin, J.D. and Dorn, I.G. (2001) Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391-426
62. Engelhardt, S. et al. (2001) Early impairment of calcium handling and altered expression of junction in hearts of mice overexpressing the β1-adrenergic receptor. FASEB J. 15, 2718-2720
63. Port, J.D. and Bristow, M.R. (2001) Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. 33, 887-905
64. Stanley, W.C. and Chandler, M.P. (2002) Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail. Rev. 7, 115-130
65. Barger, P.M. and Kelly, D.P. (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc. Med. 10, 238-245
66. Tabbibizar, R. and Maisel, A. (2002) The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr. Opin. Cardiol. 17, 340-345
67. Tsutamoto, T. et al. (1997) Attenuation ofcompensation ofendogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96, 509-516
68. Mann, D.L. (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91, 988-998
69. Yang, C.M. et al. (1997) Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc. Res. 36, 236-245
70. Beggah, A.T. et al. (2002) Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 99, 7160-7165
71. Delcayre, C. and Swynghedauw, B. (2002) Molecular mechanisms of myocardial remodeling. The role of aldosterone. J. Mol. Cell. Cardiol. 34, 1577-1584
72. Weber, K.T. (2001) Cardioreparation in hypertensive heart disease. Hypertension 38, 588-591
73. Wilson, E.M. and Spinale, F.G. (2001) Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann. Med. 33, 623-634
74. q interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280, 574-577
75. Hefti, M.A. et al. (1997) Signaling pathways in cardiac myocyte hypertrophy. J. Mol. Cell. Cardiol. 29, 2873-2892
76. Clerk, A. and Sugden, P.H. (2000) Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ. Res. 86, 1019-1023
77. Garrington, T.P. and Johnson, G.L. (1999) Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11, 211-218
78. Yamazaki, T. et al. (1995) Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. J. Clin. Invest. 96, 438-446
79. Paul, A. et al. (1997) Stress-activated protein kinases: activation, regulation and function. Cell. Signal. 9, 403-410
80. Sugden, P.H. and Clerk, A. (1998) Stress-responsive mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83, 345-352
81. Crabtree, G.R. and Olson, E.N. (2002) NFAT signaling: choreographing the social lives of cells. Cell 109 (Suppl.), S67-S79
82. Molkentin, J.D. et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215-228
83. Wilkins, B.J. and Molkentin, J.D. (2002) Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J. Physiol. 541, 1-8
84. Rothermel, B.A. et al. (2003) The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc. Med. 13, 15-21
85. Ritter, O. et al. (2002) Calcineurin in human heart hypertrophy. Circulation 105, 2265-2269
86. Ritter, O. et al. (2003) AT2 receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway. FASEB J. 17, 283-285
87. Zhang, C.L. et al. (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488
88. Pelzer, T. et al. (2002) Oestrogen action on the myocardium in vivo: specific and permissive for angiotensin-converting enzyme inhibition. J. Hypertens. 20, 1001-1006
89. Pelzer, T. et al. (2001) Estrogen effects in the myocardium: inhibition of NF-κB DNA binding by estrogen receptor-α and -β. Biochem. Biophys. Res. Commun. 286, 1153-1157
90. Pelzer, T. et al. (2000) 17β-estradiol prevents programmed cell death in cardiac myocytes. Biochem. Biophys. Res. Commun. 268, 192-200
91. Chien, K.R. (1999) Stress pathways and heart failure. Cell 98, 555-558
92. Chien, K.R. (2000) Genomic circuits and the integrative biology of cardiac diseases. Nature 407, 227-232
93. Sussman, M.A. et al. (2002) Dance band on the Titanic: biomechanical signaling in cardiac hypertrophy. Circ. Res. 91, 888-898
94. Bueno, O.F. et al. (2002) Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc. Res. 53, 806-821